الفهرس 
Breast Cancer .Only 14 pages are availabe for public view
 |  | from | 138 |  |  |
| | | from | 138 | | |
Abstract
Retrospective Study about the Prevalence of (TILs) Tumor Infiltrating Lymphocytes in Non-Metastatic Triple Negative Breast Cancer Patients and its Prognostic Value
Prof. Dr. Hesham Ahmed ElGhazaly 1, Prof. Dr. Manal Mohamed El-Mahdy 2,
Dr. Azza Mohamed Adel 1, Dr. Nermeen Mostafa 1, Aya Magdy Kamal Ali 1
1 Clinical Oncology and Nuclear Medicine, 2 Pathology Department, Faculty of Medicine, Ain Shams University
ABSTRACT
Background: TNBC comprises a distinct disease entity with a unique microenvironment of TILs, the immunogenic potential of TNBC is derived from its genetic instability and high mutation rate. Tumors from patients with TNBC are more likely than tumors from patients with other subtypes to exhibit chromosomal instability and potential mutations.
Objectives: The study aims to evaluate the prevalence of CD8+ TILs biomarker by IHC in triple negative breast cancer and its prognostic value. TILs are an important prognostic value for the response of patient to chemotherapy the greater number of TILS is associated with higher probability of response to chemotherapy also decrease recurrence. TILS in triple negative breast cancer suggest a likely option for immunotherapy in this disease.
Patients and Methods: This is a retrospective study, which was carried on 30 female patients, Clinical data and paraffin wax block of female patients with triple negative breast cancer are to be collected from the breast cancer unit, department of clinical Oncology and Nuclear medicine Ain Shams university and Matarya teaching hospital.
Results: Several large systematic reviews and meta-analyses have confirmed that high levels of TILs are associated with better disease free survival and overall survival only in triple negative and HER2 positive subtypes, with no significant benefit seen in estrogen receptor positive breast carcinoma. In the Breast International group (BIG) 02-98 trial shows that for every 10 % increase in the intertumoral TILs there was a 17 % reduced risk of relapse, and 27% reduced risk of death regardless of chemotherapy type. Also in eastern cooperative oncology group trial (ECOG) 2197, and 1199 showed that for every 10% increase in TILs, a 14% reduction of risk of recurrence, and 19% reduction in risk of death were observed.
Conclusion: Our study showed that All our patients (100%) were positive for CD8+, with a minimum range of 1% and a maximum range of 60 %, most of the patients (20 patients) had CD8 % between (10% to 20 %). High levels of CD8 + TILs are good prognostic indicators in TNBC. our study showed that there were associations of CD8+ TILs infiltrate status with longer progression free survival and better overall survival in triple-negative breast cancer, but were not statistically significant probably due to our small sample size.